A Phase 2 interventional study of Everolimus and Everolimus in Transitional Cell Carcinoma, Bladder Carcinoma and Urothelial Carcinoma, sponsored by Matthew Galsky. Terminated at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.
Sponsored by Matthew Galsky · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing paclitaxel in Carcinoma, Transitional Cell — none open to participants now, 1 under way, none of them phase 3. Paclitaxel · Carcinoma, Transitional Cell.
Among the 12 studies testing paclitaxel in Carcinoma, Transitional Cell, this one is the 9th largest by enrollment, is the only one that started in 2010, is one of 11 in phase 2, and was the 4th registered.
633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →None of the 12 studies testing paclitaxel in Carcinoma, Transitional Cell is open now. The open studies under Carcinoma, Transitional Cell, anywhere →
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 50 across 500 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 44 across the 12 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 10 most frequent:
Matthew Galsky is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Matthew Galsky has 4 studies filed under Carcinoma, Transitional Cell — fewer than ten, so there is no comparison to draw.
1 of the studies testing paclitaxel in Carcinoma, Transitional Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06632951AbbVieStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing paclitaxel in Carcinoma, Transitional Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
OUTLINE: This is a multi-center study
Patients will be enrolled into one of two parallel cohorts:
Restaging evaluations will be performed after every 2 cycles.
Treatment will continue until disease progression or unacceptable toxicity.
Karnofsky performance status 60-70%
Life Expectancy: Not specified
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance \< 60 ml/min AND Karnofsky performance status of 60-70%)
Drug: Everolimus
Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance \< 60 ml/min OR Karnofsky performance status of 60-70%)
Drug: Everolimus · Drug: Paclitaxel
10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel
To evaluate clinical benefit rate (complete response, partial response, and stable disease) at 4 months from initiation of treatment.
Time frame: 4 months
Number of Adverse Events as a Measure of Safety and Tolerability
To determine the safety of everolimus and everolimus plus paclitaxel in this patient population. A summary with the count of events per grade is provided.
Time frame: 5 months
Progression Free Survival
To determine median progression free survival per RECIST 1.1, per cohort.
Time frame: 4 months
Overall Survival
To determine median overall survival at 1-year from the initiation of treatment.
Time frame: 12 months
| Milestone | Everolimus | Everolimus Plus Paclitaxel |
|---|---|---|
| Started | 7 | 29 |
| Completed | 1 | 2 |
| Not completed | 6 | 27 |
| Withdrew: Adverse event | 2 | 9 |
| Withdrew: Disease progression | 3 | 14 |
| Withdrew: Symptomatic deterioration | 1 | 1 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
To evaluate clinical benefit rate (complete response, partial response, and stable disease) at 4 months from initiation of treatment.
| percentage of participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel | 14.3 | 37.9 |
To determine the safety of everolimus and everolimus plus paclitaxel in this patient population. A summary with the count of events per grade is provided.
| Number of Events | Cohort 1 | Cohort 2 |
|---|---|---|
| Grade 1 Adverse Events | 10 | 116 |
| Grade 2 Adverse Events | 9 | 75 |
| Grade 3 Adverse Events | 4 | 39 |
| Grade 4 Adverse Events | 0 | 1 |
| Grade 5 Adverse Events | 0 | 3 |
To determine median progression free survival per RECIST 1.1, per cohort.
| months | Cohort 1 | Cohort 2 |
|---|---|---|
| Progression Free Survival | 2.3327 (1.6099 to 3.5483) | 5.8480 (2.9569 to 7.6550) |
To determine median overall survival at 1-year from the initiation of treatment.
| months | Cohort 1 | Cohort 2 |
|---|---|---|
| Overall Survival | 4.5010 (2.2341 to 8.3121) | 10.8747 (6.8337 to 14.3573) |
Collected over All-Cause Mortality was monitored up to a maximum of 12 months. Serious Adverse Events and Other (Not Including Serious) Adverse Events were monitored for up to 5 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 7/7 (100%) | 1/7 (14.3%) | 5/7 (71.4%) |
| Cohort 2 | 25/29 (86.2%) | 11/29 (37.9%) | 28/29 (96.6%) |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| INFECTIONS AND INFESTATIONS - OTHER, SPECIFYInfections and infestations | 1/7 | 2/29 |
| PNEUMONITISRespiratory, thoracic and mediastinal disorders | 0/7 | 2/29 |
| URINARY TRACT INFECTIONInfections and infestations | 0/7 | 2/29 |
| DEHYDRATIONMetabolism and nutrition disorders | 0/7 | 1/29 |
| DIARRHEAGastrointestinal disorders | 0/7 | 1/29 |
| DYSPNEARespiratory, thoracic and mediastinal disorders | 0/7 | 1/29 |
| EDEMA LIMBSGeneral disorders | 0/7 | 1/29 |
| GENERALIZED MUSCLE WEAKNESSMusculoskeletal and connective tissue disorders | 0/7 | 1/29 |
| HEPATOBILIARY DISORDERS - OTHER, SPECIFYHepatobiliary disorders | 0/7 | 1/29 |
| LUNG INFECTIONInfections and infestations | 0/7 | 1/29 |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| ANEMIABlood and lymphatic system disorders | 2/7 | 17/29 |
| FATIGUEGeneral disorders | 3/7 | 15/29 |
| MUCOSITIS ORALGastrointestinal disorders | 2/7 | 14/29 |
| ALOPECIASkin and subcutaneous tissue disorders | 0/7 | 13/29 |
| DIARRHEAGastrointestinal disorders | 2/7 | 11/29 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 0/7 | 11/29 |
| NAUSEAGastrointestinal disorders | 1/7 | 10/29 |
| NEUTROPHIL COUNT DECREASEDInvestigations | 0/7 | 9/29 |
| HYPERTRIGLYCERIDEMIAMetabolism and nutrition disorders | 0/7 | 7/29 |
| ANOREXIAMetabolism and nutrition disorders | 1/7 | 6/29 |
| Age, Continuous(years) | Everolimus | Everolimus Plus Paclitaxel | Total |
|---|---|---|---|
| Mean | 78 (59 to 90) | 72.14 (54 to 88) | 73.28 (54 to 90) |
| Sex: Female, Male(Participants) | Everolimus | Everolimus Plus Paclitaxel | Total |
|---|---|---|---|
| Female | 2 | 7 | 9 |
| Male | 5 | 22 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Everolimus | Everolimus Plus Paclitaxel | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 7 | 28 | 35 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Everolimus | Everolimus Plus Paclitaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 5 | 27 | 32 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Everolimus | Everolimus Plus Paclitaxel | Total |
|---|---|---|---|
| United States | 7 | 29 | 36 |
| Karnovsky Performance Status (KPS) at Screening(Participants) | Everolimus | Everolimus Plus Paclitaxel | Total |
|---|---|---|---|
| KPS 100 | 0 | 4 | 4 |
| KPS 90 | 0 | 6 | 6 |
| KPS 80 | 0 | 12 | 12 |
| KPS 70 | 1 | 4 | 5 |
| KPS 60 | 6 | 3 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Dec 2010, a primary completion of Apr 2017 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2023, 6 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paclitaxel
Carcinoma, Transitional Cell →
Matthew Galsky